ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
29 juin 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing...
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
28 juin 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its...
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
26 juin 2023 16h05 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the submission...
ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
14 juin 2023 08h31 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced...
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
15 mai 2023 16h05 HE
|
ReShape Lifesciences Inc
Achieved Continued Improvement in Operational Effectiveness With First Quarter 2023 Operating Expenses Down 42.9% Compared to the First Quarter of 2022 Executing a Plan For Growth and Profitability...
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
11 mai 2023 08h30 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it...
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
27 avr. 2023 08h30 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will...
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
25 avr. 2023 16h05 HE
|
ReShape Lifesciences Inc
Continued Sequential Quarterly Growth in the U.S. With Q4 Revenues of $2.7 Million Improved Operational Effectiveness With Second Half 2022 Operating Expenses Down 27.9% Compared to the First Half of...
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
20 avr. 2023 08h30 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that...
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
11 avr. 2023 08h30 HE
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...